AACR Annual Meeting 2020 The AACR Annual Meeting program covers the latest discoveries across the spectrum of cancer research—from population science and prevention; to cancer biology, translational, and clinical ...
About ASCO Founded in 1964, the American Society of Clinical Oncology is the world's leading professional organization for physicians and oncology professionals caring for people with cancer. https://meetings.asco.org/immuno/registration-hotel?cmpid=db_immsym_rh_gadw_-_all_11-14-19_immsymhtml&cmpid=db_immsym_rh_srch_-_all_10-16-19_immsym
The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members ...
Immunomic Therapeutics’ Collaborator, University of Florida Presents New Clinical Data from ATTAC-II Study in GBM at the 2019 Society for Neurology (SNO) Annual Meeting
Nov. 20, 2019 ROCKVILLE, MD – Immunomic Therapeutics, Inc., a privately held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today that Duane Mitchell, MD, ...
November 04, 2019 08:00 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, today announced that ...
Immunomic Therapeutics to Present at the First International Symposium on Merkel Cell Carcinoma 2019
Data demonstrates that UNITE, as a nucleic acid platform, elicits potent immune responses ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. will present data on its investigational nucleic acid platform, UNITE (UNiversal ...
Discussion of UNITE platform as applied in cancer immunotherapy BOSTON--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. announced today a presentation at the Precision Lung Cancer World R&D Summit in Boston. On Tuesday, ...
Immunomic Therapeutics Assumes Sponsorship of ATTAC-II IND for ITI-1000, a Dendritic Cell Vaccine in Phase 2 for the Treatment of GBM
- ITI-1000 targets CMV with Immunomic Therapeutics’ immunotherapy UNITE™ platform - ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. announced today that it has assumed sponsorship of the Investigational New Drug (IND) ...
Immunomic Therapeutics Appoints Harvard’s Brain Tumor Expert, Dr. E. Antonio Chiocca, to its Scientific Advisory Board
ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today that it has appointed brain tumor expert E. Antonio ‘Nino’ Chiocca, M.D., Ph.D., Harvey W. ...
Precision: Lung Cancer will bring together scientists and business leaders from pharma, biotech and academia, using extensive networking sessions to forge meaningful collaborations. Discussions will revolve around translating the latest ...
United Scientific Group welcomes Fifth Edition of International Conference on Vaccines Research and Development (Vaccines R&D-2019) in Boston, MA during November 18-20, 2019. This meeting will cover broad range of ...
Presented by Maryland Life Sciences, a division of the Maryland Tech Council, the Bio Innovation Conference showcases Maryland’s innovation and successes in the life sciences industry. This conference provides a ...
